{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:24:24Z","timestamp":1765959864552},"reference-count":43,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1111\/jcpt.12477","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T17:24:48Z","timestamp":1479144288000},"page":"239-243","source":"Crossref","is-referenced-by-count":6,"title":["Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies"],"prefix":"10.1155","volume":"42","author":[{"given":"J.","family":"Goncalves","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Matos de Brito","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Lisbon Portugal"},{"name":"Faculdade de Ci\u00eancias da Sa\u00fade; Universidade da Beira Interior; Covilh\u00e3 Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Batista","sequence":"additional","affiliation":[{"name":"CHVNG; Espinho Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Feio","sequence":"additional","affiliation":[{"name":"CHUC; Hospitais da Universidade de Coimbra; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Machado","sequence":"additional","affiliation":[{"name":"CHUC; Hospitais da Universidade de Coimbra; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Aperta","sequence":"additional","affiliation":[{"name":"ULS; Guarda Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ascens\u00e3o","sequence":"additional","affiliation":[{"name":"Hospital Beatriz Angelo; Loures Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pires","sequence":"additional","affiliation":[{"name":"IPO; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Hospital Vila Franca de Xira; Vila Franca de Xira Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Armandina Pontes","sequence":"additional","affiliation":[{"name":"CH P\u00f3voa de Varzim; Vila do Conde Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alcobia","sequence":"additional","affiliation":[{"name":"Hospital Garcia de Orta; Almada Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Paulo Cruz","sequence":"additional","affiliation":[{"name":"CHLC - Hospital Santa Maria; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lampreia Guerreiro","sequence":"additional","affiliation":[{"name":"ULSBA; Beja Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Farinha","sequence":"additional","affiliation":[{"name":"Hospital Egas Moniz; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Margarida Freitas","sequence":"additional","affiliation":[{"name":"CUF-Descobertas; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Caetano","sequence":"additional","affiliation":[{"name":"CHUC; Hospitais da Universidade de Coimbra; Coimbra Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Almeida","sequence":"additional","affiliation":[{"name":"Hospital Garcia de Orta; Almada Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Costa","sequence":"additional","affiliation":[{"name":"IPO; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"IPO; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Campos","sequence":"additional","affiliation":[{"name":"Hospital Pedro Hispano; Sra. da Hora Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Madureira","sequence":"additional","affiliation":[{"name":"Hospital S\u00e3o Francisco Xavier; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Catarino","sequence":"additional","affiliation":[{"name":"British Hospital Lisbon XXI; Lisboa Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"other members presented at APFH meeting of biosimilar positioning on behalf of Portuguese Association of Hospital Pharmacists","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"10.1111\/jcpt.12477-BIB0001|jcpt12477-cit-0001","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrd2728","article-title":"Typical pitfalls in applications for marketing authorization of biotechnological products in Europe","volume":"7","author":"Schneider","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jcpt.12477-BIB0002|jcpt12477-cit-0002","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2165\/11593730-000000000-00000","article-title":"Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations","volume":"71","author":"Dranitsaris","year":"2011","journal-title":"Drugs"},{"key":"10.1111\/jcpt.12477-BIB0003|jcpt12477-cit-0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3821\/1913-701X-143.4.184","article-title":"An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: biosame or biodifferent?","volume":"143","author":"Revers","year":"2010","journal-title":"Can Pharm J"},{"volume-title":"The impact of biosimilars\u2019 entry in the EU market","year":"2011","author":"Rovira","key":"10.1111\/jcpt.12477-BIB0004|jcpt12477-cit-0004"},{"key":"10.1111\/jcpt.12477-BIB0005|jcpt12477-cit-0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd2307","article-title":"The FDA's assessment of follow-on protein products: a historical perspective","volume":"6","author":"Woodcock","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jcpt.12477-BIB0006|jcpt12477-cit-0006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0609.2010.01566.x","article-title":"Biosimilar agents in oncology\/haematology: from approval to practice","volume":"86","author":"Niederwieser","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1111\/jcpt.12477-BIB0007|jcpt12477-cit-0007","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ndt\/gfg182","article-title":"Pure red-cell aplasia due to anti-erythropoietin antibodies","volume":"18","author":"Eckardt","year":"2003","journal-title":"Nephrol Dial Transpl"},{"key":"10.1111\/jcpt.12477-BIB0008|jcpt12477-cit-0008","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMp1107285","article-title":"Developing the nation's biosimilars program","volume":"365","author":"Kozlowski","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12477-BIB0009|jcpt12477-cit-0009","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nbt.2322","article-title":"In support of the European Union biosimilar framework","volume":"30","author":"Schneider","year":"2012","journal-title":"Nat Biotech"},{"key":"10.1111\/jcpt.12477-BIB0010|jcpt12477-cit-0010","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12477-BIB0011|jcpt12477-cit-0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotech"},{"key":"10.1111\/jcpt.12477-BIB0012|jcpt12477-cit-0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nbt1030","article-title":"Characterizing biological products and assessing comparability following manufacturing changes","volume":"22","author":"Chirino","year":"2004","journal-title":"Nat Biotech"},{"key":"10.1111\/jcpt.12477-BIB0013|jcpt12477-cit-0013","unstructured":"European Medicines Agency European Public Assessment Reports for Filgrastim ratiopharm, Ratiograstim, Biograstim, Tevagrastim London EMA 2008 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d125"},{"key":"10.1111\/jcpt.12477-BIB0014|jcpt12477-cit-0014","doi-asserted-by":"crossref","first-page":"S03","DOI":"10.18553\/jmcp.2011.17.s9-b.S03","article-title":"Core management principles in rheumatoid arthritis to help guide managed care professionals","volume":"17","author":"Agarwal","year":"2011","journal-title":"J Manag Care Pharm"},{"issue":"Suppl 1","key":"10.1111\/jcpt.12477-BIB0015|jcpt12477-cit-0015","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndtplus\/sfn177","article-title":"Biosimilar therapeutics-what do we need to consider?","volume":"2","author":"Schellekens","year":"2009","journal-title":"NDT Plus"},{"key":"10.1111\/jcpt.12477-BIB0016|jcpt12477-cit-0016","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1146\/annurev.bi.57.070188.004033","article-title":"Glycobiology","volume":"57","author":"Rademacher","year":"1988","journal-title":"Annu Rev Biochem"},{"key":"10.1111\/jcpt.12477-BIB0017|jcpt12477-cit-0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/clpt.2011.343","article-title":"The state of the art in the development of biosimilars","volume":"91","author":"McCamish","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12477-BIB0018|jcpt12477-cit-0018","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.drudis.2010.06.009","article-title":"Post-translational modifications of protein biopharmaceuticals","volume":"15","author":"Walsh","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1111\/jcpt.12477-BIB0019|jcpt12477-cit-0019","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11095-010-0288-2","article-title":"Quality of original and biosimilar epoetin products","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm Res"},{"key":"10.1111\/jcpt.12477-BIB0020|jcpt12477-cit-0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3821\/1913-701X-143.3.134","article-title":"An introduction to biologics and biosimilars. Part I: Biologics: what are they and where do they come from?","volume":"143","author":"Revers","year":"2010","journal-title":"Can Pharm J"},{"key":"10.1111\/jcpt.12477-BIB0021|jcpt12477-cit-0021","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nbt0810-793","article-title":"Public biotech 2009 - the numbers","volume":"28","author":"Huggett","year":"2010","journal-title":"Nat Biotech"},{"key":"10.1111\/jcpt.12477-BIB0022|jcpt12477-cit-0022","unstructured":"Expert Committee on Biological Standardization Geneva 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs) World health Organization 2009 http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf"},{"key":"10.1111\/jcpt.12477-BIB0023|jcpt12477-cit-0023","unstructured":"US Food and Drug Administration Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product USA FDA 2015 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291134.pdf"},{"key":"10.1111\/jcpt.12477-BIB0024|jcpt12477-cit-0024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/B978-1-4160-9993-2.00033-3","volume-title":"Targeted treatment of the rheumatic diseases","author":"Strand","year":"2010"},{"key":"10.1111\/jcpt.12477-BIB0025|jcpt12477-cit-0025","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The advent of biosimilar therapies in rheumatology - \u201cO Brave New World\u201d","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1111\/jcpt.12477-BIB0026|jcpt12477-cit-0026","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","article-title":"Bioequivalence and the immunogenicity of biopharmaceuticals","volume":"1","author":"Schellekens","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 5","key":"10.1111\/jcpt.12477-BIB0027|jcpt12477-cit-0027","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/ndt\/gfl476","article-title":"Immunogenicity of biopharmaceuticals","volume":"21","author":"Kessler","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1111\/jcpt.12477-BIB0028|jcpt12477-cit-0028","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12477-BIB0029|jcpt12477-cit-0029","unstructured":"European Medicines Agency EMEA Workshop on Monoclonal Antibodies London EMA 2009 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/events\/2009\/11\/event_detail_000013.jsp&mid=WC0b01ac058004d5c3"},{"volume-title":"Guideline on Similar Biological Medicinal Products Containing Biotechnology- Derived Proteins As Active Substance: Non-Clinical and Clinical Issues","year":"2006","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1111\/jcpt.12477-BIB0030|jcpt12477-cit-0030"},{"volume-title":"Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues","year":"2006","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1111\/jcpt.12477-BIB0031|jcpt12477-cit-0031"},{"key":"10.1111\/jcpt.12477-BIB0032|jcpt12477-cit-0032","unstructured":"US Food and Drug Administration Scientific Considerations in Demonstrating Biosimilarity to a Reference Product USA FDA 2015 http:\/\/www.fda.gov\/downloads\/DrugsGuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf"},{"volume-title":"Guideline on Similar Biological Medicinal Products CHMP\/437\/04","year":"2005","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1111\/jcpt.12477-BIB0033|jcpt12477-cit-0033"},{"volume-title":"Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies-Non-Clinical and Clinical Issues EMA\/CHMP\/BMWP\/403543\/2010","year":"2012","author":"Committee for Medicinal Products for Human Use (CHMP)","key":"10.1111\/jcpt.12477-BIB0034|jcpt12477-cit-0034"},{"volume-title":"Biologics Price Competition and Innovation Act","year":"2009","author":"US Food and Drug Administration","key":"10.1111\/jcpt.12477-BIB0035|jcpt12477-cit-0035"},{"key":"10.1111\/jcpt.12477-BIB0036|jcpt12477-cit-0036","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/ard.2008.096982","article-title":"Influence of variants of Fc\u03b3 receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis","volume":"68","author":"Ca\u00f1ete","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/jcpt.12477-BIB0037|jcpt12477-cit-0037","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: a longitudinal study with 6 months of followup","volume":"39","author":"Ram\u00edrez","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1111\/jcpt.12477-BIB0038|jcpt12477-cit-0038","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.4049\/jimmunol.161.8.3862","article-title":"Therapy with monoclonal antibodies. II. The contribution of Fc\u03b3 receptor binding and the influence of CH1 and CH3 domains on in vivo effector function","volume":"161","author":"Isaacs","year":"1998","journal-title":"J Immunol"},{"key":"10.1111\/jcpt.12477-BIB0039|jcpt12477-cit-0039","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/art.23447","article-title":"Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor \u03b1-expressing cells: comparison among infliximab, etanercept, and adalimumab","volume":"58","author":"Mitoma","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12477-BIB0040|jcpt12477-cit-0040","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14712598.2012.711308","article-title":"The safety of switching between therapeutic proteins","volume":"12","author":"Ebbers","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/jcpt.12477-BIB0041|jcpt12477-cit-0041","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/jcpt.12477-BIB0042|jcpt12477-cit-0042","doi-asserted-by":"crossref","first-page":"c1","DOI":"10.1159\/000319640","article-title":"Biosimilars and regulatory authorities","volume":"117","author":"Minghetti","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/jcpt.12477-BIB0043|jcpt12477-cit-0043","doi-asserted-by":"crossref","first-page":"E467","DOI":"10.1208\/aapsj070247","article-title":"Evidence of effectiveness: how much can we extrapolate from existing studies?","volume":"7","author":"Lee","year":"2005","journal-title":"AAPS J"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12477","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12477\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T22:27:30Z","timestamp":1692570450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12477","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}